A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

  • STATUS
    Recruiting
  • End date
    Nov 19, 2023
  • participants needed
    640
  • sponsor
    Genzyme, a Sanofi Company
Updated on 3 March 2021
renal function
cyst
treatment regimen
glomerular filtration rate
chronic kidney disease
human chorionic gonadotropin
renal disease
tolvaptan
ophthalmological examination
urine osmolality

Summary

Primary Objective:

To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage

  1. and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2).

Secondary Objectives:

  • To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2).
  • To evaluate the pharmacokinetics (PK) of venglustat in Autosomal Dominant Polycystic Kidney Disease patients (Stages 1 and 2).
  • To determine the effect of venglustat on pain and fatigue, based on patient reported diary (Stages 1 and 2).
  • Safety/tolerability objective:
  • To characterize the safety profile of venglustat (Stages 1 and 2).
  • To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2).
  • To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).

Description

Study duration per participant is 26 months (maximal) per stage, including a screening period of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days after final dose of investigational medicinal product (IMP).

Details
Condition Polycystic Kidney, Autosomal Dominant
Treatment Placebo, Venglustat GZ/SAR402671, Venglustat GZ402671
Clinical Study IdentifierNCT03523728
SponsorGenzyme, a Sanofi Company
Last Modified on3 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 55 yrs?
Gender: Male or Female
Do you have Polycystic Kidney, Autosomal Dominant?
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Male or female adult with Autosomal Dominant Polycystic Kidney Disease (ADPKD) with age at the time the consent is signed
between 18 to 50 years (both inclusive) for patients from Stage 1
between 18 to 50 years (both inclusive) for patients from Stage 2 with eGFR between 45 and 89.9 mL/min/1.73 m2 during screening period
between 18 to 55 years (both inclusive) for patients from Stage 2 with eGFR between 30 and 44.9 mL/min/1.73 m2 during screening period
Diagnosis of AKPKD in patients with a family history will be based on unified Pei criteria. In the absence of a family history, the diagnosis will be based on the presence of renal cysts bilaterally, totaling at least 20, in the absence of findings suggestive of other cystic renal diseases
Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E
Total kidney volume (TKV) must be confirmed by a central reader prior to
Visit 3
Estimated glomerular filtration rate between 45 to 89.9 mL/min/1.73 m2 during screening period (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) for Stage 1
Estimated glomerular filtration rate between 30 to 89.9 mL/min/1.73 m2 during screening period (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) for Stage 2
Eligibility will be confirmed by eGFR value from one of the two first pre-randomization eGFR measurements
Stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit for hypertensive patient
Able to read, comprehend, and respond to the study questionnaires
Patient has given voluntary written informed consent before performance of any study related procedures not part of standard medical care
Patient does not have access to tolvaptan at the time of study start or tolvaptan is not indicated for treatment of patient according to treating physician (patient does not meet recommended criteria for treatment, refuses to initiate or does not tolerate treatment with tolvaptan)
The patient, if female of childbearing potential, must have a negative blood pregnancy test (-human chorionic gonadotropin [-hCG]) at the screening visit and a negative urine pregnancy test at the baseline visit
Female patients of childbearing potential and male patients must agree to practice true abstinence in line with their preferred and usual lifestyle or to use double-contraceptive methods (including a highly effective method of contraception for female participants of childbearing potential) for the entire duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of study drug

Exclusion Criteria

Systolic blood pressure >160 mm Hg at Run-in and Baseline visits
Administration within 3 months prior to the screening visit of tolvaptan or other Polycystic Kidney Disease-modifying agents (somatostatin analogues)
Current participation in another investigational interventional study or use of investigational medicinal product (IMP), within 3 months or 5 half lives, whichever is longer, before randomization
The patient has a positive result of any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti HIV1 and anti HIV2 Ab). Patients with a positive hepatitis B surface antibody (HBsAb) test are eligible if other criteria are met (ie, negative tests for: HBsAg, hepatitis B core antibody [HBcAb]). Patients immune due to natural infection (positive hepatitis B surface antigen (HBsAb), negative hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody [HBcAb]) are eligible if they have negative HBV DNA test
A history of drug and/or alcohol abuse within the past year prior to the screening visit. A history of alcohol dependence within the 5 years prior to the screening visit
The patient is scheduled for in-patient hospitalization including elective surgery, during the study
The patient has a clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the condition exacerbated during the study, or that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities
The patient, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, has contraindications to pupillary dilation or unable to undergo magnetic resonance imaging (MRI) [For example: patient's weight exceeds weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc])
Any country-related specific regulation that would prevent the patient from entering the study
The patients did not adhere to treatment (<70% compliance rate) in the run-in
The patient has, according to World Health Organization (WHO) Grading, a cortical cataract >one-quarter of the lens circumference (Grade cortical cataract-2 [COR-2]) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2 [PSC-2]). Patients with nuclear cataracts will not be excluded
The patient is currently receiving potentially cataractogenic medications, including a chronic regimen (more frequently than every 2 weeks) of any route of corticosteroids (including medium and high potency topical steroids) or any medication that may cause cataract, according to the Prescribing Information
The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives, whichever is longer, prior to randomization. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration
The patient is pregnant, or lactating
Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal unless the patient has the diagnosis of Gilbert syndrome. Patients with the Gilbert syndrome should have no additional symptoms or signs which suggest hepatobiliary disease and serum total bilirubin level no more than 3mg/dl (51 mol/L) with conjugated bilirubin less than 20% of the total bilirubin fraction
Presence of severe depression as measured by Beck Depression Inventory-II (BDI-II) >28 and/or a history of a major affective disorder within 1 year of the screening visit
Known hypersensitivity to venglustat or any component of the excipients
The above information is not intended to contain all considerations relevant
to a patient's potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note